Mabpharm, a China-based biopharmaceutical company backed by CDH Investments, saw its stock drop almost 20% on debut following a HK$1.23 billion ($157 million) IPO in Hong Kong.
According to a filing, a total of 823 million shares - including an overallocation - were sold at HK$1.50 each, the low end of the indicative range. After its debut on May 31 the stock closed at HK$1.21;...
Xyb2b.com, a B2B platform that helps Chinese e-commerce companies source products from overseas, has completed an extended Series B round of funding worth $100 million.
Beijing Ubox Online Technology, a Chinese vending machine manager, has received RMB1.6 billion ($226 million) in funding from Ant Financial Services Group and Primavera Capital Group.
CITIC Capital has scaled up for its latest China fund, raising 75% more capital than in the previous vintage. The buyout-focused GP expects tighter liquidity to drive more corporate carve-outs
Tala, a US financial technology provider looking to expand its microlending operations in India, has raised a $110 million Series D round from a group including PayPal Ventures.